The University of Chicago Header Logo

Connection

Pankti Reid to Humans

Back to Details
This is a "connection" page, showing publications Pankti Reid has written about Humans.
Pankti Reid
Connection Strength
0.492
Humans
  1. Immunotherapy Toxicity Management in Clinical Practice: Building the Clinical Infrastructure for Immune-related Adverse Event Evaluation and Care. Rheum Dis Clin North Am. 2024 05; 50(2):229-239.
    View in: PubMed
    Score: 0.030
  2. Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases. Oncoimmunology. 2023; 12(1):2261264.
    View in: PubMed
    Score: 0.030
  3. Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events. Oncologist. 2023 05 08; 28(5):440-448.
    View in: PubMed
    Score: 0.029
  4. Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events. JAMA Oncol. 2023 05 01; 9(5):723-724.
    View in: PubMed
    Score: 0.029
  5. Role-Specific Curricular Needs for Identification and Management of Immune-Related Adverse Events. J Cancer Educ. 2023 10; 38(5):1486-1492.
    View in: PubMed
    Score: 0.029
  6. Treatment of rheumatic adverse events of cancer immunotherapy. Best Pract Res Clin Rheumatol. 2022 12; 36(4):101805.
    View in: PubMed
    Score: 0.028
  7. Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy. J Clin Rheumatol. 2022 Oct 01; 28(7):367-373.
    View in: PubMed
    Score: 0.027
  8. Mortality Trends in Rheumatoid Arthritis: Zooming in on Interstitial Lung Disease. Ann Am Thorac Soc. 2021 12; 18(12):1953-1954.
    View in: PubMed
    Score: 0.026
  9. Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study. J Immunother Cancer. 2021 09; 9(9).
    View in: PubMed
    Score: 0.026
  10. Immune Checkpoint Inhibitor Therapy Toxicities-Reply. JAMA. 2021 07 06; 326(1):87-88.
    View in: PubMed
    Score: 0.025
  11. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report. J Med Case Rep. 2021 Mar 19; 15(1):124.
    View in: PubMed
    Score: 0.025
  12. Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy. JAMA. 2021 Feb 02; 325(5):482-483.
    View in: PubMed
    Score: 0.025
  13. Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis. Clin Exp Rheumatol. 2021 Nov-Dec; 39(6):1385-1393.
    View in: PubMed
    Score: 0.025
  14. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696.
    View in: PubMed
    Score: 0.024
  15. Teacher training for rheumatology fellows: a national needs assessment of fellows and program directors. Clin Rheumatol. 2020 Mar; 39(3):673-680.
    View in: PubMed
    Score: 0.023
  16. Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk. JAMA Netw Open. 2024 Nov 04; 7(11):e2446336.
    View in: PubMed
    Score: 0.008
  17. NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. J Natl Compr Canc Netw. 2024 Nov; 22(9):582-592.
    View in: PubMed
    Score: 0.008
  18. Mimickers of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis. Rheum Dis Clin North Am. 2024 05; 50(2):161-179.
    View in: PubMed
    Score: 0.008
  19. JAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol. 2023 Jul-Dec; 19(11):1385-1397.
    View in: PubMed
    Score: 0.007
  20. Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors. Drug Saf. 2023 11; 46(11):1049-1071.
    View in: PubMed
    Score: 0.007
  21. Anticitrullinated peptide antibody epitope expansion and the HLA DRB1 'shared epitope' are less common in seropositive checkpoint inhibitor-induced inflammatory arthritis than in longstanding rheumatoid arthritis. RMD Open. 2023 06; 9(2).
    View in: PubMed
    Score: 0.007
  22. Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis. 2023 07; 82(7):920-926.
    View in: PubMed
    Score: 0.007
  23. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021 08 10; 326(6):499-518.
    View in: PubMed
    Score: 0.006
  24. Socially optimal pandemic drug dosing. Lancet Glob Health. 2021 08; 9(8):e1049-e1050.
    View in: PubMed
    Score: 0.006
  25. Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations. Gynecol Oncol. 2020 09; 158(3):531-537.
    View in: PubMed
    Score: 0.006
  26. Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19. Clin Pharmacol Ther. 2020 09; 108(3):425-427.
    View in: PubMed
    Score: 0.006
  27. Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors. Am J Kidney Dis. 2019 12; 74(6):853-856.
    View in: PubMed
    Score: 0.005
  28. Facial Palsy Induced by Checkpoint Blockade: A Single Center Retrospective Study. J Immunother. 2019 04; 42(3):94-96.
    View in: PubMed
    Score: 0.005
  29. Approach to Patients with Suspected Rheumatic Disease. Prim Care. 2018 Jun; 45(2):169-180.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.